Review



nlrp3 (k232a), his-flag-tag (sf9-derived) recombinant  (BPS Bioscience)


Bioz Verified Symbol BPS Bioscience is a verified supplier
Bioz Manufacturer Symbol BPS Bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    BPS Bioscience nlrp3 (k232a), his-flag-tag (sf9-derived) recombinant
    Nlrp3 (K232a), His Flag Tag (Sf9 Derived) Recombinant, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/NLRP3+(K232A)%2C+His-FLAG-Tag+(Sf9-derived)+Recombinant/custom%4040741%4033332136
    Average 92 stars, based on 2 article reviews
    nlrp3 (k232a), his-flag-tag (sf9-derived) recombinant - by Bioz Stars, 2026-11
    92/100 stars

    Images

    Related Articles

    other:

    Article Title: Discovery of Novel 2,3-Dihydro-1 H -indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis.
    Article Snippet: The NLRP3 inflammasome is a multiprotein complex that plays a crucial role in the pathophysiology of multiple inflammation-related diseases.. In this study, we designed and synthesized a series of novel 2,3dihydro-1H-indene-5-sulfonamide analogues as NLRP3 inflammasome inhibitors, and then identified compound 15z as a potent and specific inhibitor (IC50: 0.13 μM) with low toxicity.. Mechanistic studies indicate that 15z binds directly to NLRP3 protein (KD: 102.7 nM), blocking the assembly and activation of the NLRP3 inflammasome and effectively inhibiting cell pyroptosis.

    Recombinant:

    Article Title: Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis.
    Article Snippet: The NLRP3 inflammasome is a critical component of innate immunity, which defends internal and external threats.. However, inappropriate activation of the NLRP3 inflammasome induces various human diseases.. In this study, we discovered and synthesized a series of tetrahydroquinoline inhibitors of NLRP3 inflammasome.



    Similar Products

    94
    MedChemExpress recombinant human nlrp3
    Identification of CPX as a potential inhibitor of <t>NLRP3</t> Inflammasome. (A) Screening workflow of 190 FDA‐approved drugs. The THP‐1 cells (pretreated with 200 ng/mL PMA overnight) were primed with LPS, and incubated with drugs (10 µ m ) for 1 h prior to nigericin stimulation. Then, IL‐1β secretion was quantified by ELISA. (B) IL‐1β inhibition rate in culture supernatants (Sup) from THP‐1 cells. (C) The chemical structure of CPX. (D) IC 50 of CPX on the NLRP3 inflammasome‐dependent IL‐1β secretion (0–80 µ m ). (E,F) LPS‐primed THP‐1 cells were treated with various doses of CPX or DMSO for 1 h and then stimulated with nigericin. (E) ELISA of IL‐1β in Sup from THP‐1 cells. (F) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup, and NLRP3, pro‐IL‐1β, pro‐caspase‐1, and ASC in lysates (Lys) from THP‐1 cells. (G) The cytotoxicity of CPX on THP‐1 cells was measured using the CCK‐8 kit. Data from three independent experiments (E. Values are mean ± SD) or are representative of three independent experiments(F). Statistical analyses were carried out via one‐way ANOVA for (E), ** p < 0.01, *** p < 0.001.
    Recombinant Human Nlrp3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/NLRP3%2C+Human/pmc13336122-213-6-12
    Average 94 stars, based on 1 article reviews
    recombinant human nlrp3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    OriGene recombinant nlrp3
    Molecular docking analysis. ( A ) The tested compounds (quercetin, quercetin 3- O -glucuronide, quercetin 7- O -glucuronide, isorhamnetin, isorhamnetin 3- O -glucuronide, and the positive control (MCC950) were inside the binding site of the <t>NLRP3</t> (pdb:6npy) protein. ( B ) Quercetin, isorhamnetin, and MCC950 with the interacting amino acids.
    Recombinant Nlrp3, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/NLRP3+(NM_001079821)+Human+Recombinant+Protein/pmc13210167-222-0-2
    Average 94 stars, based on 1 article reviews
    recombinant nlrp3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    OriGene recombinant human nlrp3 protein
    Molecular docking analysis. ( A ) The tested compounds (quercetin, quercetin 3- O -glucuronide, quercetin 7- O -glucuronide, isorhamnetin, isorhamnetin 3- O -glucuronide, and the positive control (MCC950) were inside the binding site of the <t>NLRP3</t> (pdb:6npy) protein. ( B ) Quercetin, isorhamnetin, and MCC950 with the interacting amino acids.
    Recombinant Human Nlrp3 Protein, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/NLRP3+(NM_004895)+Human+Recombinant+Protein/pmc13051731-357-0-7
    Average 94 stars, based on 1 article reviews
    recombinant human nlrp3 protein - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    MedChemExpress recombinant human nlrp3 protein
    Api inhibits both in vivo and in vitro activation of <t>NLRP3</t> inflammasome. (A) Relative mRNA expression of Nlrp3 in colonic tissues from Control, DSS, and DSS + Api groups (qPCR; n = 5). (B) Western-blot analysis of inflammasome-related proteins in colonic tissue: cleaved and pro-IL-1β, cleaved and pro-caspase-1, NLRP3, ASC, GSDMD; β-actin was used as a loading control. (C) ELISA quantification of IL-1β in BMDM supernatants after LPS + nigericin stimulation with or without Api ( n = 3). (D) qPCR analysis of IL-1β , Nlrp3 , and GSDMD transcripts in BMDMs under the same conditions as in (C) ( n = 3). (E) SPR sensorgram confirming the direct interaction between Api and recombinant NLRP3. (F) Molecular-docking model showing the predicted binding of Api to the NACHT domain of NLRP3 (PDB: 7ALV); calculated binding energy, −8.6 kcal/mol. ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus DSS.
    Recombinant Human Nlrp3 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/NLRP3%2C+Human/pmc12814563-87-2-15
    Average 93 stars, based on 1 article reviews
    recombinant human nlrp3 protein - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Cusabio human pyd nacht domain 1 536aa
    Api inhibits both in vivo and in vitro activation of <t>NLRP3</t> inflammasome. (A) Relative mRNA expression of Nlrp3 in colonic tissues from Control, DSS, and DSS + Api groups (qPCR; n = 5). (B) Western-blot analysis of inflammasome-related proteins in colonic tissue: cleaved and pro-IL-1β, cleaved and pro-caspase-1, NLRP3, ASC, GSDMD; β-actin was used as a loading control. (C) ELISA quantification of IL-1β in BMDM supernatants after LPS + nigericin stimulation with or without Api ( n = 3). (D) qPCR analysis of IL-1β , Nlrp3 , and GSDMD transcripts in BMDMs under the same conditions as in (C) ( n = 3). (E) SPR sensorgram confirming the direct interaction between Api and recombinant NLRP3. (F) Molecular-docking model showing the predicted binding of Api to the NACHT domain of NLRP3 (PDB: 7ALV); calculated binding energy, −8.6 kcal/mol. ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus DSS.
    Human Pyd Nacht Domain 1 536aa, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/Recombinant+Human+NACHT%2C+LRR+and+PYD+domains-containing+protein+3(NLRP3)%2Cpartial/pmc12670425-194-15-19
    Average 93 stars, based on 1 article reviews
    human pyd nacht domain 1 536aa - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Cusabio human pydnacht domain 1 536aa
    Api inhibits both in vivo and in vitro activation of <t>NLRP3</t> inflammasome. (A) Relative mRNA expression of Nlrp3 in colonic tissues from Control, DSS, and DSS + Api groups (qPCR; n = 5). (B) Western-blot analysis of inflammasome-related proteins in colonic tissue: cleaved and pro-IL-1β, cleaved and pro-caspase-1, NLRP3, ASC, GSDMD; β-actin was used as a loading control. (C) ELISA quantification of IL-1β in BMDM supernatants after LPS + nigericin stimulation with or without Api ( n = 3). (D) qPCR analysis of IL-1β , Nlrp3 , and GSDMD transcripts in BMDMs under the same conditions as in (C) ( n = 3). (E) SPR sensorgram confirming the direct interaction between Api and recombinant NLRP3. (F) Molecular-docking model showing the predicted binding of Api to the NACHT domain of NLRP3 (PDB: 7ALV); calculated binding energy, −8.6 kcal/mol. ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus DSS.
    Human Pydnacht Domain 1 536aa, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/Recombinant+Human+NACHT%2C+LRR+and+PYD+domains-containing+protein+3(NLRP3)%2Cpartial/pm41222223-228-15-19
    Average 93 stars, based on 1 article reviews
    human pydnacht domain 1 536aa - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress hy p702076 recombinant human nlrp3 gst tagged medchemexpress
    Api inhibits both in vivo and in vitro activation of <t>NLRP3</t> inflammasome. (A) Relative mRNA expression of Nlrp3 in colonic tissues from Control, DSS, and DSS + Api groups (qPCR; n = 5). (B) Western-blot analysis of inflammasome-related proteins in colonic tissue: cleaved and pro-IL-1β, cleaved and pro-caspase-1, NLRP3, ASC, GSDMD; β-actin was used as a loading control. (C) ELISA quantification of IL-1β in BMDM supernatants after LPS + nigericin stimulation with or without Api ( n = 3). (D) qPCR analysis of IL-1β , Nlrp3 , and GSDMD transcripts in BMDMs under the same conditions as in (C) ( n = 3). (E) SPR sensorgram confirming the direct interaction between Api and recombinant NLRP3. (F) Molecular-docking model showing the predicted binding of Api to the NACHT domain of NLRP3 (PDB: 7ALV); calculated binding energy, −8.6 kcal/mol. ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus DSS.
    Hy P702076 Recombinant Human Nlrp3 Gst Tagged Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nlrp3/NLRP3%2C+Human/pm40944911-277-10-15
    Average 93 stars, based on 1 article reviews
    hy p702076 recombinant human nlrp3 gst tagged medchemexpress - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Identification of CPX as a potential inhibitor of NLRP3 Inflammasome. (A) Screening workflow of 190 FDA‐approved drugs. The THP‐1 cells (pretreated with 200 ng/mL PMA overnight) were primed with LPS, and incubated with drugs (10 µ m ) for 1 h prior to nigericin stimulation. Then, IL‐1β secretion was quantified by ELISA. (B) IL‐1β inhibition rate in culture supernatants (Sup) from THP‐1 cells. (C) The chemical structure of CPX. (D) IC 50 of CPX on the NLRP3 inflammasome‐dependent IL‐1β secretion (0–80 µ m ). (E,F) LPS‐primed THP‐1 cells were treated with various doses of CPX or DMSO for 1 h and then stimulated with nigericin. (E) ELISA of IL‐1β in Sup from THP‐1 cells. (F) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup, and NLRP3, pro‐IL‐1β, pro‐caspase‐1, and ASC in lysates (Lys) from THP‐1 cells. (G) The cytotoxicity of CPX on THP‐1 cells was measured using the CCK‐8 kit. Data from three independent experiments (E. Values are mean ± SD) or are representative of three independent experiments(F). Statistical analyses were carried out via one‐way ANOVA for (E), ** p < 0.01, *** p < 0.001.

    Journal: Advanced Science

    Article Title: Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

    doi: 10.1002/advs.75704

    Figure Lengend Snippet: Identification of CPX as a potential inhibitor of NLRP3 Inflammasome. (A) Screening workflow of 190 FDA‐approved drugs. The THP‐1 cells (pretreated with 200 ng/mL PMA overnight) were primed with LPS, and incubated with drugs (10 µ m ) for 1 h prior to nigericin stimulation. Then, IL‐1β secretion was quantified by ELISA. (B) IL‐1β inhibition rate in culture supernatants (Sup) from THP‐1 cells. (C) The chemical structure of CPX. (D) IC 50 of CPX on the NLRP3 inflammasome‐dependent IL‐1β secretion (0–80 µ m ). (E,F) LPS‐primed THP‐1 cells were treated with various doses of CPX or DMSO for 1 h and then stimulated with nigericin. (E) ELISA of IL‐1β in Sup from THP‐1 cells. (F) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup, and NLRP3, pro‐IL‐1β, pro‐caspase‐1, and ASC in lysates (Lys) from THP‐1 cells. (G) The cytotoxicity of CPX on THP‐1 cells was measured using the CCK‐8 kit. Data from three independent experiments (E. Values are mean ± SD) or are representative of three independent experiments(F). Statistical analyses were carried out via one‐way ANOVA for (E), ** p < 0.01, *** p < 0.001.

    Article Snippet: Ciclopirox olamine, imiquimod, TcdB toxin, and recombinant human NLRP3 were purchased from MedChemExpress (New Jersey, USA); Phorbol‐12‐myristate‐13‐acetate(PMA), LPS, nigericin, LDH activity assay kit, MitoTracker, MitoSOX, RIPA, human IgG, penicillin/streptomycin, NP40, and protein A+G agarose were supplied by Beyotime (Shanghai, China); MSU, SiO 2 , Alum, poly(dA:dT), pronase, disuccinimidyl suberate, and anti‐MYC were purchased from Sigma (St, Louis, USA); ATP, lipofectamine 2000, and Salmonella typhimurium (FLA‐ST) were supplied by InvivoGen (New Jersey, USA); and the ADP‐Glo Kinase assay kit was purchased from Promega (WI, USA).

    Techniques: Incubation, Enzyme-linked Immunosorbent Assay, Inhibition, Western Blot, CCK-8 Assay

    CPX blocks NLRP3 inflammasome activation. (A,B) THP‐1 cells were first primed with LPS (3 h) and then treated with or without 20 µ m CPX for 1 h, followed by stimulation with ATP for 40 min, nigericin for 1 h, or MSU for 6 h. ELISA of IL‐1β in Sup (A), or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup. (C,D) LPS‐primed BMDMs were treated with 20 µ m CPX and then stimulated with ATP for 40 min, nigericin for 1 h, or MSU for 6 h. ELISA of IL‐1β in Sup (C), or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup (D). (E‐F) THP‐1 cells were primed with LPS (3 h) and then treated with or without 20 µ m CPX for 1 h, followed by stimulation with Alum for 6 h, imiquimod for 3 h, or SiO2 for 6 h. ELISA of IL‐1β in Sup (E), or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup(F). (G,H) THP‐1 cells were treated and primed with LPS (3 h) and then treated with or without 20 µ m CPX for 1 h, followed by stimulation with poly(dA:dT) for 4 h, FLA‐ST for 4 h, or TcdB for 1 h. ELISA of IL‐1β in Sup (G) or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup (H). (I) Representative microscopic images of LPS‐primed THP‐1 cells upon nigericin stimulation with or without CPX pre‐treatment (red arrows mark pyroptotic cells). Scale bars correspond to 100 µm. (J) PI (red fluorescence) and Hoechst (blue fluorescence) staining of THP‐1 cells revealed the dead cells. Scale bars correspond to 100 µm. (K) The release of LDH from LPS‐primed THP‐1 cells, pre‐treated with or without CPX and then stimulated with ATP, nigericin, or MSU. (L) Immunoblot analysis of GSDMD cleavage from THP‐1 cells, primed with LPS before treatment with or without CPX, followed by treatment with nigericin. Data from three independent experiments (A,C,E,G,K. Values are mean ± SD) or are representative of three independent experiments with similar results (B,D,F,H–J). Statistical analyses were carried out via two‐way ANOVA for (A,C,E,G,K), *** p < 0.001, NS not significant.

    Journal: Advanced Science

    Article Title: Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

    doi: 10.1002/advs.75704

    Figure Lengend Snippet: CPX blocks NLRP3 inflammasome activation. (A,B) THP‐1 cells were first primed with LPS (3 h) and then treated with or without 20 µ m CPX for 1 h, followed by stimulation with ATP for 40 min, nigericin for 1 h, or MSU for 6 h. ELISA of IL‐1β in Sup (A), or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup. (C,D) LPS‐primed BMDMs were treated with 20 µ m CPX and then stimulated with ATP for 40 min, nigericin for 1 h, or MSU for 6 h. ELISA of IL‐1β in Sup (C), or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup (D). (E‐F) THP‐1 cells were primed with LPS (3 h) and then treated with or without 20 µ m CPX for 1 h, followed by stimulation with Alum for 6 h, imiquimod for 3 h, or SiO2 for 6 h. ELISA of IL‐1β in Sup (E), or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup(F). (G,H) THP‐1 cells were treated and primed with LPS (3 h) and then treated with or without 20 µ m CPX for 1 h, followed by stimulation with poly(dA:dT) for 4 h, FLA‐ST for 4 h, or TcdB for 1 h. ELISA of IL‐1β in Sup (G) or immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup (H). (I) Representative microscopic images of LPS‐primed THP‐1 cells upon nigericin stimulation with or without CPX pre‐treatment (red arrows mark pyroptotic cells). Scale bars correspond to 100 µm. (J) PI (red fluorescence) and Hoechst (blue fluorescence) staining of THP‐1 cells revealed the dead cells. Scale bars correspond to 100 µm. (K) The release of LDH from LPS‐primed THP‐1 cells, pre‐treated with or without CPX and then stimulated with ATP, nigericin, or MSU. (L) Immunoblot analysis of GSDMD cleavage from THP‐1 cells, primed with LPS before treatment with or without CPX, followed by treatment with nigericin. Data from three independent experiments (A,C,E,G,K. Values are mean ± SD) or are representative of three independent experiments with similar results (B,D,F,H–J). Statistical analyses were carried out via two‐way ANOVA for (A,C,E,G,K), *** p < 0.001, NS not significant.

    Article Snippet: Ciclopirox olamine, imiquimod, TcdB toxin, and recombinant human NLRP3 were purchased from MedChemExpress (New Jersey, USA); Phorbol‐12‐myristate‐13‐acetate(PMA), LPS, nigericin, LDH activity assay kit, MitoTracker, MitoSOX, RIPA, human IgG, penicillin/streptomycin, NP40, and protein A+G agarose were supplied by Beyotime (Shanghai, China); MSU, SiO 2 , Alum, poly(dA:dT), pronase, disuccinimidyl suberate, and anti‐MYC were purchased from Sigma (St, Louis, USA); ATP, lipofectamine 2000, and Salmonella typhimurium (FLA‐ST) were supplied by InvivoGen (New Jersey, USA); and the ADP‐Glo Kinase assay kit was purchased from Promega (WI, USA).

    Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Fluorescence, Staining

    CPX inhibits NLRP3 inflammasome activation in vivo and in patient cells. (A–J) C57BL/6 mice were intraperitoneally injected with vehicle, CPX (10 mg/kg), or CPX (20 mg/kg) for 1 h prior to LPS injection to induce sepsis. (A) Schematic diagram of the LPS‐induced sepsis model. (B) Survival analysis of mice pretreated with vehicle or CPX (20 mg/kg) for 1 h before being intraperitoneally injected with LPS ( n = 10). (C,D) The activity of plasma ALT and AST ( n = 6). (E) Representative images of H&E‐stained liver sections. Scale bars, 50 µm. (F–I) ELISA of IL‐1β and IL‐6 in serum and in Sup from cultured liver tissues ( n = 6). (F) IL‐1β and (G) IL‐6 levels in serum. (H) IL‐1β and (I) IL‐6 levels in liver tissues. (J) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in liver tissues. (K–R) C57BL/6 mice were treated with 3% DSS in drinking water for 6 days, followed by 4 days of normal drinking water. CPX or vehicle was administered daily ( n = 6). (K) Schematic diagram of DSS‐induced colitis model. (L) Body weights, (M) the disease activity index (DAI), (N) representative colon images, and (O) colon length were measured. (P) ELISA of IL‐1β in colon tissues. (Q) H&E‐stained colon tissues. (R) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in colon tissues. (S,T) PBMCs primed with LPS and treated with 20 µ m CPX for 1 h, and then stimulated with nigericin or MSU. ELISA of IL‐1β in Sup of PBMCs isolated from healthy individuals (S) or gout patients (T). Date from three independent experiments (S,T. Values are mean ± SD). Statistical analyses were carried out via two‐way ANOVA for (B–D, F–L, L,M, O,P, S,T), * p < 0.05, ** p < 0.01, *** p < 0.001, NS not significant.

    Journal: Advanced Science

    Article Title: Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

    doi: 10.1002/advs.75704

    Figure Lengend Snippet: CPX inhibits NLRP3 inflammasome activation in vivo and in patient cells. (A–J) C57BL/6 mice were intraperitoneally injected with vehicle, CPX (10 mg/kg), or CPX (20 mg/kg) for 1 h prior to LPS injection to induce sepsis. (A) Schematic diagram of the LPS‐induced sepsis model. (B) Survival analysis of mice pretreated with vehicle or CPX (20 mg/kg) for 1 h before being intraperitoneally injected with LPS ( n = 10). (C,D) The activity of plasma ALT and AST ( n = 6). (E) Representative images of H&E‐stained liver sections. Scale bars, 50 µm. (F–I) ELISA of IL‐1β and IL‐6 in serum and in Sup from cultured liver tissues ( n = 6). (F) IL‐1β and (G) IL‐6 levels in serum. (H) IL‐1β and (I) IL‐6 levels in liver tissues. (J) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in liver tissues. (K–R) C57BL/6 mice were treated with 3% DSS in drinking water for 6 days, followed by 4 days of normal drinking water. CPX or vehicle was administered daily ( n = 6). (K) Schematic diagram of DSS‐induced colitis model. (L) Body weights, (M) the disease activity index (DAI), (N) representative colon images, and (O) colon length were measured. (P) ELISA of IL‐1β in colon tissues. (Q) H&E‐stained colon tissues. (R) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in colon tissues. (S,T) PBMCs primed with LPS and treated with 20 µ m CPX for 1 h, and then stimulated with nigericin or MSU. ELISA of IL‐1β in Sup of PBMCs isolated from healthy individuals (S) or gout patients (T). Date from three independent experiments (S,T. Values are mean ± SD). Statistical analyses were carried out via two‐way ANOVA for (B–D, F–L, L,M, O,P, S,T), * p < 0.05, ** p < 0.01, *** p < 0.001, NS not significant.

    Article Snippet: Ciclopirox olamine, imiquimod, TcdB toxin, and recombinant human NLRP3 were purchased from MedChemExpress (New Jersey, USA); Phorbol‐12‐myristate‐13‐acetate(PMA), LPS, nigericin, LDH activity assay kit, MitoTracker, MitoSOX, RIPA, human IgG, penicillin/streptomycin, NP40, and protein A+G agarose were supplied by Beyotime (Shanghai, China); MSU, SiO 2 , Alum, poly(dA:dT), pronase, disuccinimidyl suberate, and anti‐MYC were purchased from Sigma (St, Louis, USA); ATP, lipofectamine 2000, and Salmonella typhimurium (FLA‐ST) were supplied by InvivoGen (New Jersey, USA); and the ADP‐Glo Kinase assay kit was purchased from Promega (WI, USA).

    Techniques: Activation Assay, In Vivo, Injection, Activity Assay, Clinical Proteomics, Staining, Enzyme-linked Immunosorbent Assay, Cell Culture, Western Blot, Isolation

    CPX inhibits NLRP3 inflammasome assembly. (A) ELISA of TNF‐α in Sup from THP‐1 cells treated with various doses of CPX and then stimulated with 500 ng/mL LPS for 3 h. (B) ELISA of TNF‐α and (C) immunoblot analysis of NLRP3, pro‐caspase‐1, pro‐IL‐1β, and ASC in Lys from THP‐1 cells treated with 20 µ m CPX before or after stimulation with 500 ng/mL LPS for 3 h. (D,E) Qualification of potassium and chloride ions in LPS‐primed THP‐1 cells pretreated with or without 20 µ m CPX and then stimulated with nigericin. (F,G) Qualification of mtROS in THP‐1 cells was primed with LPS, pre‐treated with or without CPX, and subsequently stimulated with nigericin. (H) Immunoblot analysis of ASC oligomerization. (I) Representative images of ASC specks detected by immunofluorescence. DAPI shows nuclei, and white arrows show an example of ASC specks formed. Scale bar corresponds to 50 µm. (J) Percentage of ASC speck‐positive cells. (K) IP and immunoblot analysis to evaluate the NLRP3‐ASC interaction in LPS‐primed THP‐1 cells pretreated with CPX and then stimulated with nigericin. (L) IP and immunoblot analysis of HEK‐293T cells transfected with FLAG‐NLRP3, HIS‐ASC plasmids as indicated and treated with CPX. (M) IP and immunoblot analysis to evaluate the NLRP3‐NEK7 interaction in LPS‐primed THP‐1 cells pretreated with CPX and then stimulated with nigericin. (N) IP and immunoblot analysis of HEK‐293T cells transfected with FLAG‐NLRP3, MYC‐NEK7 plasmids as indicated, and treated with the CPX Data from three independent experiments(A,B,D,E,G,J. Values are mean ± SD) or are representative of three independent experiments with similar results(F,H,I,K–N). Statistical analyses were carried out via two‐way ANOVA for (A,B,D,E,G,J), *** p < 0.001, NS not significant.

    Journal: Advanced Science

    Article Title: Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

    doi: 10.1002/advs.75704

    Figure Lengend Snippet: CPX inhibits NLRP3 inflammasome assembly. (A) ELISA of TNF‐α in Sup from THP‐1 cells treated with various doses of CPX and then stimulated with 500 ng/mL LPS for 3 h. (B) ELISA of TNF‐α and (C) immunoblot analysis of NLRP3, pro‐caspase‐1, pro‐IL‐1β, and ASC in Lys from THP‐1 cells treated with 20 µ m CPX before or after stimulation with 500 ng/mL LPS for 3 h. (D,E) Qualification of potassium and chloride ions in LPS‐primed THP‐1 cells pretreated with or without 20 µ m CPX and then stimulated with nigericin. (F,G) Qualification of mtROS in THP‐1 cells was primed with LPS, pre‐treated with or without CPX, and subsequently stimulated with nigericin. (H) Immunoblot analysis of ASC oligomerization. (I) Representative images of ASC specks detected by immunofluorescence. DAPI shows nuclei, and white arrows show an example of ASC specks formed. Scale bar corresponds to 50 µm. (J) Percentage of ASC speck‐positive cells. (K) IP and immunoblot analysis to evaluate the NLRP3‐ASC interaction in LPS‐primed THP‐1 cells pretreated with CPX and then stimulated with nigericin. (L) IP and immunoblot analysis of HEK‐293T cells transfected with FLAG‐NLRP3, HIS‐ASC plasmids as indicated and treated with CPX. (M) IP and immunoblot analysis to evaluate the NLRP3‐NEK7 interaction in LPS‐primed THP‐1 cells pretreated with CPX and then stimulated with nigericin. (N) IP and immunoblot analysis of HEK‐293T cells transfected with FLAG‐NLRP3, MYC‐NEK7 plasmids as indicated, and treated with the CPX Data from three independent experiments(A,B,D,E,G,J. Values are mean ± SD) or are representative of three independent experiments with similar results(F,H,I,K–N). Statistical analyses were carried out via two‐way ANOVA for (A,B,D,E,G,J), *** p < 0.001, NS not significant.

    Article Snippet: Ciclopirox olamine, imiquimod, TcdB toxin, and recombinant human NLRP3 were purchased from MedChemExpress (New Jersey, USA); Phorbol‐12‐myristate‐13‐acetate(PMA), LPS, nigericin, LDH activity assay kit, MitoTracker, MitoSOX, RIPA, human IgG, penicillin/streptomycin, NP40, and protein A+G agarose were supplied by Beyotime (Shanghai, China); MSU, SiO 2 , Alum, poly(dA:dT), pronase, disuccinimidyl suberate, and anti‐MYC were purchased from Sigma (St, Louis, USA); ATP, lipofectamine 2000, and Salmonella typhimurium (FLA‐ST) were supplied by InvivoGen (New Jersey, USA); and the ADP‐Glo Kinase assay kit was purchased from Promega (WI, USA).

    Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Immunofluorescence, Transfection

    CPX directly targets NLRP3 and inhibits its oligomerization. (A) The schematic shows the steps for identifying the target of CPX in THP‐1 cells using drug affinity responsive target stability (DARTS) and mass spectrometry analysis. (B) Coomassie blue staining of DARTS assay using THP‐1 cell lysates treated with or without CPX. (C) The target protein of CPX was identified by mass spectrogram. (D) DARTS in THP‐1 cells incubation with CPX or DMSO. (E) DARTS in HEK‐293T cells transfected with the FLAG‐NLRP3 plasmid under incubation with CPX or DMSO. (F) CESTA of NLRP3 in THP‐1 cells incubated with CPX or DMSO. (G) The melting curve generated from CETSA. (H) The oligomerization of NLRP3 in THP‐1 cells treated with CPX was analyzed by native‐PAGE. (I) NLRP3 oligomerization in HEK‐293T cells expressing FLAG‐NLRP3 plasmids and treated with CPX. (J) IP and immunoblot analysis of HEK‐293T cells transfected with FLAG‐NLRP3 and MYC‐NLRP3 plasmids as indicated and treated with CPX. (K) ELISA of IL‐1β in Sup and immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup from WT and NLRP3 −/− BMDMs were first primed with LPS and then treated with CPX, followed by stimulation with nigericin. (L) ELISA of IL‐1β in Sup and immunoblot analysis in Lys from HEK‐293T cells transfected with HA‐IL‐1β, HA‐pro‐caspase‐1, HIS‐ASC, with or without FLAG‐NLRP3 plasmids as indicated and treated with CPX. Data from three independent experiments (G,K,L. Values are mean ± SD) or are representative of three independent experiments with similar results (D,F,H–L). Statistical analyses were carried out via two‐way ANOVA for (K,L), ** p < 0.01, *** p < 0.001, NS not significant.

    Journal: Advanced Science

    Article Title: Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

    doi: 10.1002/advs.75704

    Figure Lengend Snippet: CPX directly targets NLRP3 and inhibits its oligomerization. (A) The schematic shows the steps for identifying the target of CPX in THP‐1 cells using drug affinity responsive target stability (DARTS) and mass spectrometry analysis. (B) Coomassie blue staining of DARTS assay using THP‐1 cell lysates treated with or without CPX. (C) The target protein of CPX was identified by mass spectrogram. (D) DARTS in THP‐1 cells incubation with CPX or DMSO. (E) DARTS in HEK‐293T cells transfected with the FLAG‐NLRP3 plasmid under incubation with CPX or DMSO. (F) CESTA of NLRP3 in THP‐1 cells incubated with CPX or DMSO. (G) The melting curve generated from CETSA. (H) The oligomerization of NLRP3 in THP‐1 cells treated with CPX was analyzed by native‐PAGE. (I) NLRP3 oligomerization in HEK‐293T cells expressing FLAG‐NLRP3 plasmids and treated with CPX. (J) IP and immunoblot analysis of HEK‐293T cells transfected with FLAG‐NLRP3 and MYC‐NLRP3 plasmids as indicated and treated with CPX. (K) ELISA of IL‐1β in Sup and immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup from WT and NLRP3 −/− BMDMs were first primed with LPS and then treated with CPX, followed by stimulation with nigericin. (L) ELISA of IL‐1β in Sup and immunoblot analysis in Lys from HEK‐293T cells transfected with HA‐IL‐1β, HA‐pro‐caspase‐1, HIS‐ASC, with or without FLAG‐NLRP3 plasmids as indicated and treated with CPX. Data from three independent experiments (G,K,L. Values are mean ± SD) or are representative of three independent experiments with similar results (D,F,H–L). Statistical analyses were carried out via two‐way ANOVA for (K,L), ** p < 0.01, *** p < 0.001, NS not significant.

    Article Snippet: Ciclopirox olamine, imiquimod, TcdB toxin, and recombinant human NLRP3 were purchased from MedChemExpress (New Jersey, USA); Phorbol‐12‐myristate‐13‐acetate(PMA), LPS, nigericin, LDH activity assay kit, MitoTracker, MitoSOX, RIPA, human IgG, penicillin/streptomycin, NP40, and protein A+G agarose were supplied by Beyotime (Shanghai, China); MSU, SiO 2 , Alum, poly(dA:dT), pronase, disuccinimidyl suberate, and anti‐MYC were purchased from Sigma (St, Louis, USA); ATP, lipofectamine 2000, and Salmonella typhimurium (FLA‐ST) were supplied by InvivoGen (New Jersey, USA); and the ADP‐Glo Kinase assay kit was purchased from Promega (WI, USA).

    Techniques: Mass Spectrometry, Staining, Incubation, Transfection, Plasmid Preparation, Generated, Clear Native PAGE, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay

    CPX binds to tyrosine 381 of the NACHT domain. (A,B) LPS‐primed THP‐1 cells were treated with CPX for 30 min and washed out, then stimulated with nigericin. (A) ELISA of IL‐1β in Sup. (B) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup. (C) Schematic of the protein domains of NLRP3. (D–F) DARTS in HEK293T transfected with (D) FLAG‐NACHT domain, (E) FLAG‐PYD domain, and (F) FLAG‐LRR domain plasmids under incubation with CPX or DMSO. (G,H) The binding affinity of CPX to the NLRP3‐NACHT domain was measured by SPR assay. (I) Molecular docking analysis of CPX bound to NLRP3‐NACHT domain. CPX (yellow, stick model) in the binding site of NLRP3‐NACHT domain (lavender, cartoon, and PDB ID: 7ALV). (J) Structural comparison of the complex at five moments (0, 25, 50, 75, 100 ns) during a 100 ns molecular dynamics simulation. (K) Energy contribution of amino acid residues involved in binding. (L) DARTS in HEK293T transfected with R167A NACHT domain or Y381A NACHT domain plasmids under incubation with CPX or DMSO. (M) IP and immunoblot analysis of HEK293T cells transfected with MYC‐NEK7, FLAG‐NLRP3, or Y381A mutant FLAG‐NLRP3 plasmids and treated with 20 µ m CPX. (N) IP and immunoblot analysis of HEK293T cells transfected with HIS‐ASC, FLAG‐NLRP3, or Y381A mutant FLAG‐NLRP3 plasmids and treated with 20 µ m CPX. (O) NLRP3 oligomerization in HEK‐293T cells transfected with FLAG‐NLRP3 or Y381A mutant FLAG‐NLRP3 plasmids and treated with CPX. (R) LPS‐primed NLRP3‐/‐ BMDMs reconstituted with WT or Y381A mutant NLRP3, were treated with CPX and then stimulated with nigericin. ELISA of IL‐1β in Sup, immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup. (Q) ATPase activity assay for purified human NLRP3 in the presence of different concentrations of CPX. Data from three independent experiments (A, P, Q. Values are mean ± SD) or are representative of three independent experiments with similar results (B, D–F, L–P). Statistical analyses were carried out via two‐way ANOVA for (A, P, Q), ** p < 0.01, *** p < 0.001, NS not significant.

    Journal: Advanced Science

    Article Title: Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

    doi: 10.1002/advs.75704

    Figure Lengend Snippet: CPX binds to tyrosine 381 of the NACHT domain. (A,B) LPS‐primed THP‐1 cells were treated with CPX for 30 min and washed out, then stimulated with nigericin. (A) ELISA of IL‐1β in Sup. (B) Immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup. (C) Schematic of the protein domains of NLRP3. (D–F) DARTS in HEK293T transfected with (D) FLAG‐NACHT domain, (E) FLAG‐PYD domain, and (F) FLAG‐LRR domain plasmids under incubation with CPX or DMSO. (G,H) The binding affinity of CPX to the NLRP3‐NACHT domain was measured by SPR assay. (I) Molecular docking analysis of CPX bound to NLRP3‐NACHT domain. CPX (yellow, stick model) in the binding site of NLRP3‐NACHT domain (lavender, cartoon, and PDB ID: 7ALV). (J) Structural comparison of the complex at five moments (0, 25, 50, 75, 100 ns) during a 100 ns molecular dynamics simulation. (K) Energy contribution of amino acid residues involved in binding. (L) DARTS in HEK293T transfected with R167A NACHT domain or Y381A NACHT domain plasmids under incubation with CPX or DMSO. (M) IP and immunoblot analysis of HEK293T cells transfected with MYC‐NEK7, FLAG‐NLRP3, or Y381A mutant FLAG‐NLRP3 plasmids and treated with 20 µ m CPX. (N) IP and immunoblot analysis of HEK293T cells transfected with HIS‐ASC, FLAG‐NLRP3, or Y381A mutant FLAG‐NLRP3 plasmids and treated with 20 µ m CPX. (O) NLRP3 oligomerization in HEK‐293T cells transfected with FLAG‐NLRP3 or Y381A mutant FLAG‐NLRP3 plasmids and treated with CPX. (R) LPS‐primed NLRP3‐/‐ BMDMs reconstituted with WT or Y381A mutant NLRP3, were treated with CPX and then stimulated with nigericin. ELISA of IL‐1β in Sup, immunoblot analysis of matured‐IL‐1β and cleaved caspase‐1 in Sup. (Q) ATPase activity assay for purified human NLRP3 in the presence of different concentrations of CPX. Data from three independent experiments (A, P, Q. Values are mean ± SD) or are representative of three independent experiments with similar results (B, D–F, L–P). Statistical analyses were carried out via two‐way ANOVA for (A, P, Q), ** p < 0.01, *** p < 0.001, NS not significant.

    Article Snippet: Ciclopirox olamine, imiquimod, TcdB toxin, and recombinant human NLRP3 were purchased from MedChemExpress (New Jersey, USA); Phorbol‐12‐myristate‐13‐acetate(PMA), LPS, nigericin, LDH activity assay kit, MitoTracker, MitoSOX, RIPA, human IgG, penicillin/streptomycin, NP40, and protein A+G agarose were supplied by Beyotime (Shanghai, China); MSU, SiO 2 , Alum, poly(dA:dT), pronase, disuccinimidyl suberate, and anti‐MYC were purchased from Sigma (St, Louis, USA); ATP, lipofectamine 2000, and Salmonella typhimurium (FLA‐ST) were supplied by InvivoGen (New Jersey, USA); and the ADP‐Glo Kinase assay kit was purchased from Promega (WI, USA).

    Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Transfection, Incubation, Binding Assay, SPR Assay, Comparison, Mutagenesis, Activity Assay, Purification

    The mechanism of CPX blocking NLRP3 inflammasome activation.

    Journal: Advanced Science

    Article Title: Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

    doi: 10.1002/advs.75704

    Figure Lengend Snippet: The mechanism of CPX blocking NLRP3 inflammasome activation.

    Article Snippet: Ciclopirox olamine, imiquimod, TcdB toxin, and recombinant human NLRP3 were purchased from MedChemExpress (New Jersey, USA); Phorbol‐12‐myristate‐13‐acetate(PMA), LPS, nigericin, LDH activity assay kit, MitoTracker, MitoSOX, RIPA, human IgG, penicillin/streptomycin, NP40, and protein A+G agarose were supplied by Beyotime (Shanghai, China); MSU, SiO 2 , Alum, poly(dA:dT), pronase, disuccinimidyl suberate, and anti‐MYC were purchased from Sigma (St, Louis, USA); ATP, lipofectamine 2000, and Salmonella typhimurium (FLA‐ST) were supplied by InvivoGen (New Jersey, USA); and the ADP‐Glo Kinase assay kit was purchased from Promega (WI, USA).

    Techniques: Blocking Assay, Activation Assay

    Molecular docking analysis. ( A ) The tested compounds (quercetin, quercetin 3- O -glucuronide, quercetin 7- O -glucuronide, isorhamnetin, isorhamnetin 3- O -glucuronide, and the positive control (MCC950) were inside the binding site of the NLRP3 (pdb:6npy) protein. ( B ) Quercetin, isorhamnetin, and MCC950 with the interacting amino acids.

    Journal: Pharmaceuticals

    Article Title: In Silico and In Vitro Evaluation of Quercetin Metabolites Binding to Inflammatory Target Proteins

    doi: 10.3390/ph19050655

    Figure Lengend Snippet: Molecular docking analysis. ( A ) The tested compounds (quercetin, quercetin 3- O -glucuronide, quercetin 7- O -glucuronide, isorhamnetin, isorhamnetin 3- O -glucuronide, and the positive control (MCC950) were inside the binding site of the NLRP3 (pdb:6npy) protein. ( B ) Quercetin, isorhamnetin, and MCC950 with the interacting amino acids.

    Article Snippet: Recombinant NLRP3 (Origene, TP750176) was labeled with the Monolith Protein Labeling Kit RED-NHS 2nd Generation (Cat. No. M0-L011, NanoTemper Technologies, Munich, Germany).

    Techniques: Positive Control, Binding Assay

    Binding of quercetin, isorhamnetin, quercetin 7- O -glucuronide, quercetin 3- O -glucuronide, isorhamnetin 3- O -glucuronide, tamarixetin, hippuric acid, and 3,4-dihydroxytoluene to NLRP3 as determined by microscale thermophoresis.

    Journal: Pharmaceuticals

    Article Title: In Silico and In Vitro Evaluation of Quercetin Metabolites Binding to Inflammatory Target Proteins

    doi: 10.3390/ph19050655

    Figure Lengend Snippet: Binding of quercetin, isorhamnetin, quercetin 7- O -glucuronide, quercetin 3- O -glucuronide, isorhamnetin 3- O -glucuronide, tamarixetin, hippuric acid, and 3,4-dihydroxytoluene to NLRP3 as determined by microscale thermophoresis.

    Article Snippet: Recombinant NLRP3 (Origene, TP750176) was labeled with the Monolith Protein Labeling Kit RED-NHS 2nd Generation (Cat. No. M0-L011, NanoTemper Technologies, Munich, Germany).

    Techniques: Binding Assay, Microscale Thermophoresis

    Api inhibits both in vivo and in vitro activation of NLRP3 inflammasome. (A) Relative mRNA expression of Nlrp3 in colonic tissues from Control, DSS, and DSS + Api groups (qPCR; n = 5). (B) Western-blot analysis of inflammasome-related proteins in colonic tissue: cleaved and pro-IL-1β, cleaved and pro-caspase-1, NLRP3, ASC, GSDMD; β-actin was used as a loading control. (C) ELISA quantification of IL-1β in BMDM supernatants after LPS + nigericin stimulation with or without Api ( n = 3). (D) qPCR analysis of IL-1β , Nlrp3 , and GSDMD transcripts in BMDMs under the same conditions as in (C) ( n = 3). (E) SPR sensorgram confirming the direct interaction between Api and recombinant NLRP3. (F) Molecular-docking model showing the predicted binding of Api to the NACHT domain of NLRP3 (PDB: 7ALV); calculated binding energy, −8.6 kcal/mol. ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus DSS.

    Journal: Journal of Agricultural and Food Chemistry

    Article Title: Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis

    doi: 10.1021/acs.jafc.5c15405

    Figure Lengend Snippet: Api inhibits both in vivo and in vitro activation of NLRP3 inflammasome. (A) Relative mRNA expression of Nlrp3 in colonic tissues from Control, DSS, and DSS + Api groups (qPCR; n = 5). (B) Western-blot analysis of inflammasome-related proteins in colonic tissue: cleaved and pro-IL-1β, cleaved and pro-caspase-1, NLRP3, ASC, GSDMD; β-actin was used as a loading control. (C) ELISA quantification of IL-1β in BMDM supernatants after LPS + nigericin stimulation with or without Api ( n = 3). (D) qPCR analysis of IL-1β , Nlrp3 , and GSDMD transcripts in BMDMs under the same conditions as in (C) ( n = 3). (E) SPR sensorgram confirming the direct interaction between Api and recombinant NLRP3. (F) Molecular-docking model showing the predicted binding of Api to the NACHT domain of NLRP3 (PDB: 7ALV); calculated binding energy, −8.6 kcal/mol. ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus DSS.

    Article Snippet: Commercially available recombinant human NLRP3 protein (CSB-EP822275HU7) and AMPK α1/β2/γ1 heterotrimer protein (HY- P76143 , MCE) were immobilized (∼3,000 RU) on a CM5 Chip (GE Healthcare, Piscataway, NJ, USA) according to a standard amine coupling procedure.

    Techniques: In Vivo, In Vitro, Activation Assay, Expressing, Control, Western Blot, Enzyme-linked Immunosorbent Assay, Recombinant, Binding Assay

    Api alleviates colitis by coordinately modulating AMPK and NLRP3. (A-B) ELISA quantification of TNF-α, IL-6 (A), and IL-1β (B) in BMDM supernatants following LPS + nigericin stimulation with or without Api, the AMPK agonist AICAR, or the AMPK inhibitor BAY-3827 ( n = 4). (C) Effect of AMPKα1 knockdown on the mRNA expression of Prkaa1 , TNF-α , and Nlrp3 in BMDMs subjected to LPS + nigericin stimulation with or without Api treatment ( n = 6). (D) SPR sensorgram confirming the direct interaction between Api and the recombinant AMPK α1/β2/γ1 complex. (E) Molecular-docking models depicting Api bound to multiple reported AMPK allosteric or activator-related pockets, including AMPKα1 (PDB: 6C9F), AMPKα1β1γ1 (PDB: 6C9F), AMPKα1β1γ1 (PDB: 4QFR), and AMPKα2β1γ1 (PDB: 4CFF).

    Journal: Journal of Agricultural and Food Chemistry

    Article Title: Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis

    doi: 10.1021/acs.jafc.5c15405

    Figure Lengend Snippet: Api alleviates colitis by coordinately modulating AMPK and NLRP3. (A-B) ELISA quantification of TNF-α, IL-6 (A), and IL-1β (B) in BMDM supernatants following LPS + nigericin stimulation with or without Api, the AMPK agonist AICAR, or the AMPK inhibitor BAY-3827 ( n = 4). (C) Effect of AMPKα1 knockdown on the mRNA expression of Prkaa1 , TNF-α , and Nlrp3 in BMDMs subjected to LPS + nigericin stimulation with or without Api treatment ( n = 6). (D) SPR sensorgram confirming the direct interaction between Api and the recombinant AMPK α1/β2/γ1 complex. (E) Molecular-docking models depicting Api bound to multiple reported AMPK allosteric or activator-related pockets, including AMPKα1 (PDB: 6C9F), AMPKα1β1γ1 (PDB: 6C9F), AMPKα1β1γ1 (PDB: 4QFR), and AMPKα2β1γ1 (PDB: 4CFF).

    Article Snippet: Commercially available recombinant human NLRP3 protein (CSB-EP822275HU7) and AMPK α1/β2/γ1 heterotrimer protein (HY- P76143 , MCE) were immobilized (∼3,000 RU) on a CM5 Chip (GE Healthcare, Piscataway, NJ, USA) according to a standard amine coupling procedure.

    Techniques: Enzyme-linked Immunosorbent Assay, Knockdown, Expressing, Recombinant